How Private Equity Firms Evaluate Medical Practices: A Data-First Guide
Private equity has deployed hundreds of billions into healthcare. The firms that compound well share one discipline: they underwrite the clinical data, not just the financials.
April 10, 2026 · Devanshu Patel · 9 min read
Quick Answer
Private equity firms evaluate medical practices by analyzing four layers of data: financial performance (revenue, EBITDA, and payer mix), operational performance (provider productivity, volume trends, and billing efficiency), clinical risk (provider concentration and referral network stability), and integration risk (data infrastructure quality and management capability). The firms that underwrite well go beyond management-provided financials into EHR encounter data — because the patterns that predict whether current performance is durable or fragile only appear at the CPT and encounter level.
The Standard Diligence Package and Its Blind Spots
A typical sell-side data room for a medical practice contains three to five years of tax returns and practice financials, a quality of earnings report, a payer mix summary, physician compensation agreements, and some form of billing report. This package answers the question every buyer needs to answer: what has this practice earned, and is it sustainable?
The honest answer to that second question is: you don't know from the documents in the data room. The information to answer it is in the EHR — and it isn't in the data room.
Here's what the standard package systematically cannot tell you:
Whether the revenue is concentrated in one or two physicians who are near retirement. The financials show total revenue. They may show revenue by location. They almost never show revenue or wRVU production attributable to individual providers — which means a buyer can close a deal, lose the physician who generated 60% of revenue eighteen months later, and have no analytical warning that this was the risk they were accepting.
Whether the referral network has been contracting. Practices that depend on referrals from health systems, multispecialty groups, or individual PCPs have a referral network that is either growing, stable, or eroding. Which it is shows up in the EHR as a pattern in the source of inbound referrals over time. A referral network that peaked two years ago and has been slowly declining is not visible in a static payer mix summary.
Whether the payer mix quality is actually as good as it looks. Payer mix percentages in a financial package are backward-looking and often averaged. What they don't show is whether specific payer contracts are up for renewal, whether reimbursement rates on key CPT codes have been drifting down, or whether the practice has been growing volume in lower-reimbursing segments to offset the rate compression. Those signals live in encounter-level reimbursement data.
What a Data-First Evaluation Actually Looks Like
Private equity firms that approach healthcare practice evaluation with a data-first discipline use EHR-level due diligence analytics to close the gap between what the data room shows and what the practice's operational reality is.
Provider Productivity Analysis
The first analytical layer is encounter volume and wRVU production by provider, trended monthly over 36 months. This analysis answers three questions simultaneously.
First, is the practice's revenue growth organic or provider-addition driven? Organic volume growth from an established provider base is durable. Revenue that grew because the practice added three physicians last year is contingent on retaining all three.
Second, which providers are the practice's primary revenue generators, and what is the risk profile associated with each? A practice where two physicians generate 70% of wRVUs — both over 60, neither with a long-term employment agreement — is a fundamentally different asset than the financial documents suggest.
Third, are any individual providers showing a volume decline? A physician who was producing 6,000 wRVUs annually two years ago and is tracking to 4,200 this year may be burned out, winding down toward retirement, or experiencing a health issue. That signal is invisible in the P&L and visible in 36 months of monthly wRVU data.
Payer Mix Trajectory Analysis
Payer mix quality is not static, and a point-in-time summary misleads buyers into treating it as if it were. The right analysis looks at how payer mix has shifted over 36 months at the procedure and encounter level.
Practices that have been quietly growing their Medicaid volume to fill capacity — because their commercial referral network has been contracting — show strong encounter volume growth in the financials but compressed reimbursement in the underlying data. The practice is working harder and earning proportionally less, and the trajectory gets worse before the revenue impact is fully visible.
Reimbursement rate variance is the companion analysis: actual collections per CPT code by payer, compared month over month. Declining realization rates on core procedure codes signal contract erosion before it flows through to the income statement.
Practice Performance Benchmarking
Raw numbers need context. A collection rate of 93% means nothing without knowing whether that's above or below the specialty and regional peer average. A denial rate of 8% is catastrophic in some specialties and normal in others. Benchmarking against national standards using MGMA data and regional peer comparisons turns point-in-time metrics into actionable intelligence about where the practice stands relative to the market.
Benchmarking also surfaces improvement opportunities that factor into the investment thesis. A practice with an 87% collection rate when the regional peer average is 93% has a quantifiable revenue recovery opportunity that can be modeled into the value creation plan before close.
What to Look For in the Integration Assessment
The quality of a practice's existing data infrastructure is a proxy for integration complexity and cost. A practice that has been running on spreadsheets and manual billing reports is going to take six to nine months and meaningful internal resources to instrument properly post-close. A practice that has an EHR data pipeline, clean CPT-level billing records, and provider-level productivity tracking is weeks from being reporting-ready under new ownership.
We recommend evaluating post-acquisition analytics readiness explicitly as part of the diligence process. The questions to ask: Does the practice have an analytics infrastructure? What does it produce? Who owns it? How dependent is it on specific individuals? What does it cost to maintain post-close?
The integration timeline — and the EBITDA impact of that timeline — is materially different for a practice that is analytics-ready versus one that isn't.
The Due Diligence Data Request That Most Sellers Will Grant
The practical obstacle to EHR-level due diligence is data access. Sellers are appropriately reluctant to open their EHR to buyers they haven't closed with. The key is structuring the data request correctly.
The request that most sellers will grant is for structured, de-identified exports from the EHR's built-in analytics module — encounter volume by provider, CPT code distribution, payer mix by encounter, and AR aging — combined with billing system exports that can be joined to EHR data via encounter identifiers. This is materially different from requesting API access to the live EHR, which sellers rarely agree to pre-close.
The data set this produces is sufficient to conduct a rigorous provider productivity analysis, payer mix trajectory assessment, and revenue integrity evaluation. It won't cover everything — some analysis requires more complete data that is only available post-close — but it surfaces the risk profile well enough to underwrite with confidence.
The buyers who ask for this data and know what to do with it are the ones who price deals most accurately and face the fewest post-close surprises.
Working on a healthcare acquisition or building your diligence process? Schedule a discovery call and let us show you what EHR-level analysis adds to what you're already doing.
Key Takeaways
- The standard data room answers the wrong question: financial diligence tells you what a practice has earned, not whether that earning is durable — EHR encounter data answers the durability question.
- Provider concentration is the most common hidden deal risk: 36 months of monthly wRVU production by provider reveals concentration, trend, and departure risk that no financial document surfaces.
- Payer mix needs to be evaluated as a trajectory, not a point-in-time number: practices growing Medicaid volume to fill eroding commercial capacity look fine on a payer mix summary and show margin compression in the encounter-level data.
- Realization rate variance is a leading indicator of contract erosion: declining actual collections per CPT code by payer signals fee schedule deterioration 6-12 months before it appears in the income statement.
- Analytics infrastructure readiness belongs in the diligence checklist: a practice that can't produce daily EHR-level reporting will cost the buyer 6-9 months and significant resources to instrument post-close.
- The right data request is structured exports, not API access: sellers will grant de-identified encounter exports and billing data far more readily than EHR API access — and that data set is sufficient for rigorous pre-close analysis.